Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys
Open accessAbstract
Replication-deficient chimpanzee adenovirus (ChAd) vectors represent an attractive vaccine platform and are thus employed as vaccine candidates against several infectious diseases. Since inducing effective immunity depends on the interplay between innate and adaptive immunity, a deeper understanding of innate immune responses elicited by intramuscularly injected ChAd vectors in tissues can advance the platform’s development. Using different candidate vaccines based on the Group C ChAd type 155 (ChAd155) vector, we characterized early immune responses in injected muscles and draining lymph nodes (dLNs) from mice, and complemented these analyses by evaluating cytokine responses and gene expression patterns in peripheral blood from ChAd155-injected macaques. In mice, vector DNA levels gradually decreased post-immunization, but local transgene mRNA expression exhibited two transient peaks [at 6 h and Day (D)5], which were most obvious in dLNs. This dynamic pattern was mirrored by the innate responses in tissues, which developed as early as 1–3 h (cytokines/chemokines) or D1 (immune cells) post-vaccination. They were characterized by a CCL2- and CXCL9/10-dominated chemokine profile, peaking at 6 h (with CXCL10/CCL2 signals also detectable in serum) and D7, and clear immune-cell infiltration peaks at D1/D2 and D6/D7. Experiments with a green fluorescent protein-expressing ChAd155 vector revealed infiltrating hematopoietic cell subsets at the injection site. Cell infiltrates comprised mostly monocytes in muscles, and NK cells, T cells, dendritic cells, monocytes, and B cells in dLNs. Similar bimodal dynamics were observed in whole-blood gene signatures in macaques: most of the 17 enriched immune/innate signaling pathways were significantly upregulated at D1 and D7 and downregulated at D3, and clustering analysis revealed stronger similarities between D1 and D7 signatures versus the D3 signature. Serum cytokine responses (CXCL10, IL1Ra, and low-level IFN-α) in macaques were predominantly observed at D1. Altogether, the early immune responses exhibited bimodal kinetics with transient peaks at D1/D2 and D6/D7, mostly with an IFN-associated signature, and these features were remarkably consistent across most analyzed parameters in murine tissues and macaque blood. These compelling observations reveal a novel aspect of the dynamics of innate immunity induced by ChAd155-vectored vaccines, and contribute to ongoing research to better understand how adenovectors can promote vaccine-induced immunity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 have been shown to induce type I interferon.
“Both BNT162b2 and mRNA-1273, as well as the adenoviral-vectored vaccine ChAdOx1 nCoV-19, have been shown to induce type I interferon, thus potentially inducing pathogen-agnostic protection75–77.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038 · see citing works
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 757 · see citing works
Self-citationCalabrό, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., Gregorio, E. D., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 431 · see citing works
Pathway level analysis of gene expression using singular value decomposition
Tomfohr, J. K., Lü, J., & Kepler, T. B. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-225 · Cited by 421 · see citing works
Hauser, A. E., Debes, G. F., Arce, S., Cassese, G., Hamann, A., Radbruch, A., & Manz, R. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1277 · Cited by 362 · see citing works
Swadling, L., Capone, S., Antrobus, R., Brown, A., Richardson, R., Newell, E. W., Halliday, J., Kelly, C., Bowen, D., Fergusson, J. R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009185 · Cited by 344 · see citing works
Self-citationColloca, S., Barnes, E. J., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 299 · see citing works
Self-citationLanglet, C., Tamoutounour, S., Henri, S., Luche, H., Ardouin, L., Grégoire, C., MALISSEN, B., & Guilliams, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102744 · Cited by 284 · see citing works
Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400948 · Cited by 266 · see citing works
Self-citationHickman, H. D., Reynoso, G. V., Ngudiankama, B. F., Cush, S. S., Gibbs, J. S., Bennink, J. R., & Yewdell, J. W. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.009 · Cited by 218 · see citing works
Hendrickx, R., Stichling, N., Koelen, J. A., Kuryk, Ł., Lipiec, A., & Greber, U. F. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.001 · Cited by 212 · see citing works
Type 1 Interferons and Antiviral CD8 T-Cell Responses
Welsh, R. M., Bahl, K., Marshall, H. D., & Urban, S. L. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002352 · Cited by 189 · see citing works
Development of stable liquid formulations for adenovirus-based vaccines
Evans, R. K., Nawrocki, D. K., Isopi, L. A., Williams, D. M., Casimiro, D. R., Chin, S., Chen, M., Zhu, D., Shiver, J. W., & Volkin, D. B. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20157 · Cited by 164 · see citing works
Adenovirus Hexon Protein Is a Potent Adjuvant for Activation of a Cellular Immune Response
Molinier‐Frenkel, V., Lengagne, R., Gaden, F., Hong, S. S., Choppin, J., Gahéry‐Ségard, H., Boulanger, P. A., & Guillet, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.1.127-135.2002 · Cited by 164 · see citing works
Teigler, J. E., Iampietro, M. J., & Barouch, D. H. (2012) · Journal of Virology · doi:10.1128/jvi.00740-12 · Cited by 129 · see citing works
Graham, S., McLean, R., Spencer, A. J., Belij-Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 126 · see citing works
Wang, H., Horbinski, C., Wu, H., Liu, Y., Sheng, S., Liu, J., Weiss, H. L., Stromberg, A. J., & Wang, C. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw677 · Cited by 122 · see citing works
Skeletal muscle cells actively shape (auto)immune responses
Afzali, A. M., Müntefering, T., Wiendl, H., Meuth, S. G., & Ruck, T. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.12.005 · Cited by 115 · see citing works
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling
Quinn, K. M., Zak, D. E., Costa, A. D. S., Yamamoto, A., Kastenmüller, K., Hill, B. J., Lynn, G. M., Darrah, P. A., Lindsay, R. W. B., Wang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78280 · Cited by 110 · see citing works
Quinn, K. M., Costa, A. D. S., Yamamoto, A., Berry, D., Lindsay, R. W. B., Darrah, P. A., Wang, L., Cheng, C., Kong, W., Gall, J. G. D., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202861 · Cited by 109 · see citing works
Chimpanzee-origin adenovirus vectors as vaccine carriers
Tatsis, N., Tesema, L., Robinson, E., Giles‐Davis, W., McCoy, K., Gao, G., Wilson, J. M., & Ertl, H. C. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302675 · Cited by 93 · see citing works
Capone, S., D’Alise, A. M., Ammendola, V., et al. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.15 · Cited by 87 · see citing works
Self-citationSung, R. S., Qin, L., & Bromberg, J. S. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0318 · Cited by 83 · see citing works
Adenoviruses Types, Cell Receptors and Local Innate Cytokines in Adenovirus Infection
Chen, R., & Lee, C. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.823420 · Cited by 82 · see citing works
Rhee, E. G., Blattman, J. N., Kasturi, S. P., Kelley, R., Kaufman, D. R., Lynch, D. M., Porte, A. L., Simmons, N. L., Clark, S., Pulendran, B., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01597-10 · Cited by 79 · see citing works
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley, S. E., Cun, A. S., Giles-Davis, W., Li, Y., Xiang, Z., Lasaro, M. O., Williams, B. R. G., Silverman, R. H., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300024 · Cited by 78 · see citing works
Development of novel vaccine vectors: Chimpanzee adenoviral vectors
Guo, J., Mondal, M., & Zhou, D. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1419108 · Cited by 78 · see citing works
Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target
Crescioli, C., Sottili, M., Bonini, P., Cosmi, L., Chiarugi, P., Romagnani, P., Vannelli, G. B., Colletti, M., Isidori, A. M., Serio, M., et al. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.011 · Cited by 77 · see citing works
Tapia, M. D., Sow, S. O., Ndiaye, B., Mbaye, K. D., Thiongane, A., N'Dour, C. T., Mboup, S., Ake, J. A., Keshinro, B., Akintunde, A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30016-5 · Cited by 74 · see citing works
Lindsay, R. W. B., Darrah, P. A., Quinn, K. M., Wille-Reece, U., Mattei, L. M., Iwasaki, A., Kasturi, S. P., Pulendran, B., Gall, J. G. D., Spies, A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000338 · Cited by 69 · see citing works
Viral vectors as vaccine carriers
Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 59 · see citing works
Cicconi, P., Jones, C., Sarkar, E., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz653 · Cited by 56 · see citing works
Regulators of T‐cell fate: Integration of cell migration, differentiation and function
Groom, J. R. (2019) · Immunological Reviews · doi:10.1111/imr.12742 · Cited by 55 · see citing works
Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
Vitelli, A., Folgori, A., Scarselli, E., Colloca, S., Capone, S., & Nicosia, A. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1394842 · Cited by 48 · see citing works
Self-citationGreen, C., Sande, C., Scarselli, E., Capone, S., Vitelli, A., Nicosia, A., Silva-Reyes, L., Thompson, A., de Lara, C. M., Taylor, K., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.02.003 · Cited by 45 · see citing works
Self-citationDicks, M. D. J., Spencer, A. J., Coughlan, L., et al. (2015) · Scientific Reports · doi:10.1038/srep16756 · Cited by 45 · see citing works
Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques
Liang, F., Ploquin, A., Hernández, J. D., Fausther‐Bovendo, H., Lindgren, G., Stanley, D. A., Salvador, A., Brenchley, J. M., Koup, R. A., Loré, K., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.06.011 · Cited by 33 · see citing works
Napolitano, F., Merone, R., Abbate, A., Ammendola, V., Horncastle, E., Lanzaro, F., Esposito, M., Contino, A. M., Sbrocchi, R., Sommella, A., et al. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008459 · Cited by 28 · see citing works
Self-citationRoy, S., Jaeson, M. I., Li, Z., Mahboob, S., Jackson, R. J., Grubor‐Bauk, B., Wijesundara, D. K., Gowans, E. J., & Ranasinghe, C. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.01.045 · Cited by 21 · see citing works
Johnson, M. J., Björkström, N. K., Petrovas, C., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.055 · Cited by 21 · see citing works
Progress in human gene therapy
Feuerbach, F. J., & Crystal, R. G. (1996) · Kidney International · doi:10.1038/ki.1996.269 · Cited by 16 · see citing works
Infected Cells Call Their Killers to the Scene of the Crime
Beura, L. K., & Masopust, D. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.001 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [11]Tapia MD Sow SO Mbaye KD Thiongane A Ndiaye BP Ndour CT Safety, Reactogenicity, and Immunogenicity of a Chimpanzee Adenovirus Vectored Ebola Vaccine in Children in Africa: a Randomised, Observer-Blind, Placebo-Controlled, Phase 2 Trial. Lancet Infect Dis (2020) 20(6): 719–30. 10.1016/S1473-3099(20)30019-0 32199492 · DOI
Cited by
Sorted by citations
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
- Authors
- Collignon, C., Bol, V., Chalon, A., Surendran, N., Morel, S., van den Berg, R. A., Capone, S., Bechtold, V., & Temmerman, S. T.
- Affiliations
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Temmerman, Stéphane T.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-30
- Volume
- 11
- Pages
- 579872-579872
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC7734297
- OpenAlex
- W3109164312
- Cited by
- 29
- References
- 45
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 4
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- GlaxoSmithKline
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Keywords
- vaccine adjuvants, innate immune response, chemokine profile, MCP-1, CXCL10, CXCL9, draining lymph nodes, intramuscular injection, immune cell infiltration, interferon signaling, macaque, mice
- MeSH terms
- Adenoviridae, Animals, Pan troglodytes, Female, Genetic Vectors, Immunity, Cellular, Immunity, Innate, Injections, Intramuscular, Interferons, Mice, Inbred C57BL, Vaccination, Vaccines, Cytokines, Chemokines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
